Nautilus Biotechnology Reports Third Quarter 2026 Financial Results
Nautilus Biotechnology reported Q3 2026 revenue of $0.2 million, primarily grant and early-access service revenue, with a net loss of $15.6 million versus $13.6 million a year ago. Operating expenses rose 10% YoY to $16.9 million, and the company held $114.3 million in cash, equivalents and investments at quarter end. Business highlights included a Nature Methods publication on Iterative Mapping, early oncology proteoform assay data, and entry into the ARPA-H-funded SEEDS consortium with up to $6 million expected for Nautilus.
Key figures
- Net loss
- 15600000
- Operating expenses
- 16900000
- Prior year net loss
- 13600000
- Cash and investments
- 114300000
- Opex yoy increase pct
- 10%
- Arpa h funding potential
- $6 million
- Planned assays through mid 2028
- 20
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.